Clinical trial · Interventional
A Study to Investigate the Food Effect on the Pharmacokinetics of Ensartinib Capsules in Chinese Healthy Volunteers.
A Pharmacokinetic Study in Chinese Healthy Male and Female Volunteers to Investigate the Effect of Food on the Pharmacokinetics of Ensartinib Capsules.
NCT03510611CI-TRIAL-00039690completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main objective of this study is to evaluate the Effect of Food on the Pharmacokinetics of Ensartinib Capsules.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ensartinib with fed or fasting | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Period 1: fed control → Period 2: fasted control
- description
- Period 1: administration of Ensartinib 225mg at 7:30am, 30 minutes after the breakfast;Period 2: administration of Ensartinib 225mg at 7:30am, without the breakfast
- interventionNames
- Drug: Ensartinib with fed or fasting
- type
- EXPERIMENTAL
- label
- Period 1: fasted control → Period 2: fed control
- description
- Period 1: administration of Ensartinib 225mg at 7:30am, without the breakfast;Period 2: administration of Ensartinib 225mg at 7:30am, 30 minutes after the breakfast
- interventionNames
- Drug: Ensartinib with fed or fasting
Primary outcomes (4)
- measure
- Peak plasma concentration (Cmax) of Ensartinib
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria: * age: 20 - 45 years; * sex: male and female; * body weight: Male ≥ 50 kg,female ≥ 45 kg, body mass index BMI (weight (kg)/height 2 (m2)) between 19-26 kg/m2 (including border); * Healthy as judged by the investigator/subinvestigator based on the results of physical examinations and all lab tests; * written informed consent; Exclusion Criteria: * Received any investigational drugs within 14 days before the screening test; * Donated 200 mL of whole blood within 30 days before the screening test,or Donated 200 mL of whole blood during the study or within 30 days after completion of the study; * Females who are lactating, pregnant, potentially child-bearing, or willing to get pregnant during the study period; * History of drug or food allergies; * Abnormal blood pressure or pulse,Abnormal laboratory tests; * Participated in other clinical trials within 3 months before screening; * Smoking and drinking within 3 months before screening or test results of smoke, alcohol, and drug abuse are positive;Positive for HBsAg, Hepatitis C virus (HCV) antibody, HIV antibody or syphilis antibody;Clinically apparent disease/infection within 1 month before screening; * Positive for HBsAg, Hepatitis C virus (HCV) antibody, HIV antibody or syphilis antibody; * Clinically apparent disease/infection within 1 month before screening;
References
Publications (0)
Data not yet available
No reference posted for this study.